Go Pro
→ Elon's next move will be bigger than the IPO – and it could happen any day now (From Brownstone Research) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cingulate Inc. stock logo
CING
Cingulate
$5.05
+2.2%		$4.82
$3.16
▼
$11.89
$66.54M-0.9181,333 shs96,388 shs
Clene Inc. stock logo
CLNN
Clene
$5.34
-0.7%		$5.77
$3.50
▼
$13.50
$68.75M0.9660,293 shs22,206 shs
MediciNova, Inc. stock logo
MNOV
MediciNova
$1.36
+2.3%		$1.34
$1.17
▼
$1.96
$65.46M0.6338,579 shs18,646 shs
ZIVO Bioscience, Inc. stock logo
ZIVO
ZIVO Bioscience
$4.02
+0.5%		$4.17
$1.11
▼
$19.65
$16.69M0.143,153 shs100 shs
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cingulate Inc. stock logo
CING
Cingulate
+0.82%+8.83%-6.79%-5.54%-8.86%
Clene Inc. stock logo
CLNN
Clene
+1.89%+13.98%-10.48%-27.20%+45.80%
MediciNova, Inc. stock logo
MNOV
MediciNova
+2.31%+3.10%-7.64%-6.99%-2.21%
ZIVO Bioscience, Inc. stock logo
ZIVO
ZIVO Bioscience
0.00%+0.00%-23.81%+0.00%-70.37%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cingulate Inc. stock logo
CING
Cingulate
$5.05
+2.2%		$4.82
$3.16
▼
$11.89
$66.54M-0.9181,333 shs96,388 shs
Clene Inc. stock logo
CLNN
Clene
$5.34
-0.7%		$5.77
$3.50
▼
$13.50
$68.75M0.9660,293 shs22,206 shs
MediciNova, Inc. stock logo
MNOV
MediciNova
$1.36
+2.3%		$1.34
$1.17
▼
$1.96
$65.46M0.6338,579 shs18,646 shs
ZIVO Bioscience, Inc. stock logo
ZIVO
ZIVO Bioscience
$4.02
+0.5%		$4.17
$1.11
▼
$19.65
$16.69M0.143,153 shs100 shs
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cingulate Inc. stock logo
CING
Cingulate
+0.82%+8.83%-6.79%-5.54%-8.86%
Clene Inc. stock logo
CLNN
Clene
+1.89%+13.98%-10.48%-27.20%+45.80%
MediciNova, Inc. stock logo
MNOV
MediciNova
+2.31%+3.10%-7.64%-6.99%-2.21%
ZIVO Bioscience, Inc. stock logo
ZIVO
ZIVO Bioscience
0.00%+0.00%-23.81%+0.00%-70.37%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Cingulate Inc. stock logo
CING
Cingulate
2.50
Moderate Buy$27.33441.25% Upside
Clene Inc. stock logo
CLNN
Clene
2.71
Moderate Buy$33.25522.66% Upside
MediciNova, Inc. stock logo
MNOV
MediciNova
2.67
Moderate Buy$8.33512.75% Upside
ZIVO Bioscience, Inc. stock logo
ZIVO
ZIVO Bioscience
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest ZIVO, MNOV, CING, and CLNN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/30/2026
Clene Inc. stock logo
CLNN
Clene
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
7/24/2026
Cingulate Inc. stock logo
CING
Cingulate
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
7/15/2026
Clene Inc. stock logo
CLNN
Clene
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
7/9/2026
Cingulate Inc. stock logo
CING
Cingulate
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
6/26/2026
Clene Inc. stock logo
CLNN
Clene
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
6/24/2026
MediciNova, Inc. stock logo
MNOV
MediciNova
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
6/11/2026
Clene Inc. stock logo
CLNN
Clene
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
6/8/2026
Cingulate Inc. stock logo
CING
Cingulate
Ascendiant Capital Markets logo
Ascendiant Capital Markets
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetBuy$55.00 ➝ $52.00
5/26/2026
Clene Inc. stock logo
CLNN
Clene
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
5/26/2026
Cingulate Inc. stock logo
CING
Cingulate
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$20.00
5/22/2026
Cingulate Inc. stock logo
CING
Cingulate
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
(Data available from 8/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Cingulate Inc. stock logo
CING
Cingulate
N/AN/AN/AN/A$0.31 per shareN/A
Clene Inc. stock logo
CLNN
Clene
$200K341.23N/AN/A($1.62) per share-3.30
MediciNova, Inc. stock logo
MNOV
MediciNova
$410K163.27N/AN/A$0.85 per share1.60
ZIVO Bioscience, Inc. stock logo
ZIVO
ZIVO Bioscience
$15.85K1,053.06N/AN/A($0.81) per share-4.96
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Cingulate Inc. stock logo
CING
Cingulate
-$22.45M-$4.23N/AN/AN/AN/A-365.15%-158.55%8/18/2026 (Estimated)
Clene Inc. stock logo
CLNN
Clene
-$26.17M-$3.20N/AN/AN/A-25,009.70%N/A-137.98%8/13/2026 (Estimated)
MediciNova, Inc. stock logo
MNOV
MediciNova
-$12M-$0.23N/AN/AN/A-1,962.98%-27.28%-25.24%8/13/2026 (Estimated)
ZIVO Bioscience, Inc. stock logo
ZIVO
ZIVO Bioscience
-$7.78M-$1.71N/AN/AN/AN/AN/A-2,240.92%9/2/2026 (Estimated)

Latest ZIVO, MNOV, CING, and CLNN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
9/2/2026N/A
ZIVO Bioscience, Inc. stock logo
ZIVO
ZIVO Bioscience
-$0.28N/AN/AN/A$0.20 millionN/A
8/18/2026Q2 2026
Cingulate Inc. stock logo
CING
Cingulate
-$0.63N/AN/AN/A$0.17 millionN/A
8/13/2026Q2 2026
Clene Inc. stock logo
CLNN
Clene
-$0.37N/AN/AN/A$0.06 millionN/A
8/13/2026Q2 2026
MediciNova, Inc. stock logo
MNOV
MediciNova
-$0.06N/AN/AN/A$0.08 millionN/A
5/14/2026Q1 2026
Cingulate Inc. stock logo
CING
Cingulate
-$0.53-$0.95-$0.42-$0.95N/AN/A
5/14/2026Q1 2026
Clene Inc. stock logo
CLNN
Clene
-$0.6367-$0.69-$0.0533-$0.69$0.05 million$0.02 million
5/14/2026Q1 2026
MediciNova, Inc. stock logo
MNOV
MediciNova
-$0.06-$0.05+$0.01-$0.05$0.19 million$0.19 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Cingulate Inc. stock logo
CING
Cingulate
N/AN/AN/AN/AN/A
Clene Inc. stock logo
CLNN
Clene
N/AN/AN/AN/AN/A
MediciNova, Inc. stock logo
MNOV
MediciNova
N/AN/AN/AN/AN/A
ZIVO Bioscience, Inc. stock logo
ZIVO
ZIVO Bioscience
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Cingulate Inc. stock logo
CING
Cingulate
N/A
2.55
2.55
Clene Inc. stock logo
CLNN
Clene
N/A
1.94
1.93
MediciNova, Inc. stock logo
MNOV
MediciNova
N/A
9.09
9.09
ZIVO Bioscience, Inc. stock logo
ZIVO
ZIVO Bioscience
N/A
0.17
0.17

Institutional Ownership

CompanyInstitutional Ownership
Cingulate Inc. stock logo
CING
Cingulate
41.31%
Clene Inc. stock logo
CLNN
Clene
23.28%
MediciNova, Inc. stock logo
MNOV
MediciNova
9.90%
ZIVO Bioscience, Inc. stock logo
ZIVO
ZIVO Bioscience
12.83%

Insider Ownership

CompanyInsider Ownership
Cingulate Inc. stock logo
CING
Cingulate
5.30%
Clene Inc. stock logo
CLNN
Clene
28.30%
MediciNova, Inc. stock logo
MNOV
MediciNova
14.00%
ZIVO Bioscience, Inc. stock logo
ZIVO
ZIVO Bioscience
48.90%
CompanyEmployeesShares OutstandingFree FloatOptionable
Cingulate Inc. stock logo
CING
Cingulate
2013.47 million12.76 millionNot Optionable
Clene Inc. stock logo
CLNN
Clene
10012.78 million9.16 millionNo Data
MediciNova, Inc. stock logo
MNOV
MediciNova
1049.22 million42.33 millionOptionable
ZIVO Bioscience, Inc. stock logo
ZIVO
ZIVO Bioscience
104.15 million2.91 millionNot Optionable

Recent News About These Companies

ZIVO Bioscience (NASDAQ:ZIVO) Share Price Crosses Below 200-Day Moving Average - Here's Why
July 29, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30927836
Zivo Bioscience, Inc. Announces Transition to OTCID Marketplace
May 12, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260512411739/en/zivo-bioscience-inc.-announces-transition-to-otcid-marketplace/
Zivo Bioscience Inc. Wt
April 11, 2026  |  barrons.comhttps://www.barrons.com/market-data/stocks/zivow
ZIVO Bioscience Provides Special Letter to Shareholders
March 27, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260327190358/en/ZIVO-Bioscience-Provides-Special-Letter-to-Shareholders/
Maxim Group Reaffirms Their Hold Rating on Zivo Bioscience (ZIVO)
December 15, 2025  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/ZIVO/pressreleases/36474537/maxim-group-reaffirms-their-hold-rating-on-zivo-bioscience-zivo/
ZIVO Bioscience releases letter to shareholders
September 14, 2025  |  wattagnet.comW
ZIVO Bioscience CEO Letter to Shareholders Highlights Progress with Human Nutrition and Animal Therapeutic Businesses
September 10, 2025  |  businesswire.comhttps://www.businesswire.com/news/home/20250910182550/en/zivo-bioscience-ceo-letter-to-shareholders-highlights-progress-with-human-nutrition-and-animal-therapeutic-businesses/
ZIVO Bioscience and Leading Global Animal Health Company to Advance ZIVO's Immune-Enhancing Compounds in Poultry
June 20, 2025  |  businesswire.comhttps://www.businesswire.com/news/home/20250620564330/en/zivo-bioscience-and-leading-global-animal-health-company-to-advance-zivo%e2%80%99s-immune-enhancing-compounds-in-poultry/
University of Delaware Study Identifies Optimal Formulation of ZIVO’s Active Ingredients for Further Testing to Mitigate Avian Influenza in Poultry
May 7, 2025  |  finance.yahoo.comhttps://finance.yahoo.com/news/university-delaware-study-identifies-optimal-215400486.html
University of Delaware Study Identifies Optimal Formulation of ZIVO's Active Ingredients for Further Testing to Mitigate Avian Influenza in Poultry
May 6, 2025  |  businesswire.comhttps://www.businesswire.com/news/home/20250506414477/en/university-of-delaware-study-identifies-optimal-formulation-of-zivo%e2%80%99s-active-ingredients-for-further-testing-to-mitigate-avian-influenza-in-poultry/
ZIVO Bioscience Plans New Study with University of Delaware to Combat Avian Influenza in Poultry
February 6, 2025  |  businesswire.comhttps://www.businesswire.com/news/home/20250206639313/en/zivo-bioscience-plans-new-study-with-university-of-delaware-to-combat-avian-influenza-in-poultry/
Zivo Bioscience issues new shares, raises $1.5 million
January 28, 2025  |  msn.comhttps://www.msn.com/en-us/money/top-stocks/zivo-bioscience-issues-new-shares-raises-1-5-million/ar-AA1xZjTM
Tuesday's Insider Activity: Top Buys and Sells in US Stocks Revealed
January 1, 2025  |  investing.comhttps://www.investing.com/news/stock-market-news/tuesdays-insider-activity-top-buys-and-sells-in-us-stocks-revealed-93CH-3793355
ZIVO Bioscience Reports Preliminary Efficacy of its Proprietary Active Ingredients in the Battle Against Avian Influenza
December 20, 2024  |  businesswire.comhttps://www.businesswire.com/news/home/20241220941955/en/ZIVO-Bioscience-Reports-Preliminary-Efficacy-of-its-Proprietary-Active-Ingredients-in-the-Battle-Against-Avian-Influenza/
ZIVO Stock Earnings: Zivo Bioscience Reported Results for Q4 2023
March 18, 2024  |  investorplace.comhttps://investorplace.com/earning-results/2024/03/zivo-stock-earnings-zivo-bioscience-for-q4-of-2023/?utm_source=marketbeat&utm_medium=referral
Harmony Biosciences Holdings
March 4, 2024  |  forbes.comhttps://www.forbes.com/companies/harmony-biosciences-holdings/
Regencell Bioscience Holdings Ltd RGC
February 1, 2024  |  morningstar.comM
ZIVO Bioscience Announces Uplisting to OTCQB Market
January 29, 2024  |  finance.yahoo.comhttps://finance.yahoo.com/news/zivo-bioscience-announces-uplisting-otcqb-130000877.html?.tsrc=rss
Ideaya Biosciences
January 18, 2024  |  forbes.comhttps://www.forbes.com/companies/ideaya-biosciences/
Dare Bioscience Inc DARE
January 14, 2024  |  morningstar.comM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
SK hynix logo above a robotic arm placing memory chips on a wafer in a server data center.
Why SK hynix Could Be the Best AI Chip Stock to Buy Now
By Thomas Hughes | July 29, 2026
SanDisk logo above a 1TB Extreme Pro microSD memory card resting on a wooden table.
Sandisk: What the Chart Is Trying to Tell Us
By Sam Quirke | July 17, 2026
Micron logo with a silicon wafer, memory modules, and semiconductor chip stack in a lab setting.
Why Micron Is Doubling Down While the HBM Shortage Persists
By Thomas Hughes | July 13, 2026
Steam rises from a power plant cooling tower silhouetted against a glowing sunset sky.
3 Energy Stocks Racing to Fix AI's Power Problem
By Bridget Bennett | July 14, 2026
Illustration of the Apple logo glowing on a circuit board encased in a translucent box against a digital backdrop.
Apple’s AI Toll Booth Thesis Faces Its Biggest Test Yet Before Earnings
By Sam Quirke | July 15, 2026
Cingulate stock logo

Cingulate NASDAQ:CING

$5.05 +0.11 (+2.23%)
Closing price 04:00 PM Eastern
Extended Trading
$5.04 -0.01 (-0.20%)
As of 06:36 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Cingulate Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company's stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults. It also focuses on developing CTx-2103 that is in a formulation stage for the treatment of anxiety. The company was founded in 2012 and is headquartered in Kansas City, Kansas.

Clene stock logo

Clene NASDAQ:CLNN

$5.34 -0.04 (-0.74%)
Closing price 04:00 PM Eastern
Extended Trading
$5.32 -0.01 (-0.28%)
As of 04:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company also develops CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease and to provide immune support for symptom resolution. In addition, it markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.

MediciNova stock logo

MediciNova NASDAQ:MNOV

$1.36 +0.03 (+2.26%)
Closing price 04:00 PM Eastern
Extended Trading
$1.38 +0.02 (+1.47%)
As of 05:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID. The company's product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic and other diseases, including nonalcoholic fatty liver disease and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. It has license agreements with Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals, Ltd.; and Meiji Seika Kaisha, Ltd. The company was incorporated in 2000 and is headquartered in La Jolla, California.

ZIVO Bioscience stock logo

ZIVO Bioscience NASDAQ:ZIVO

$4.02 +0.02 (+0.50%)
As of 09:53 AM Eastern

ZIVO Bioscience, Inc., a research and development company, engages in licensing and selling natural bioactive ingredients derived from its proprietary algae cultures to animal, human, and dietary supplement and medical food manufacturers. The company operates in the biotech and agtech sectors, with an intellectual property portfolio comprising proprietary algal and bacterial strains, biologically active molecules and complexes, production techniques, cultivation techniques, and patented or patent-pending inventions for applications in human and animal health. Its products indications include poultry gut health, bovine mastitis, canine joint health, human immune modification, algal biomass for human consumption, and biomass for supporting skin health / anti-aging. The company was formerly known as Health Enhancement Products, Inc. and changed its name to ZIVO Bioscience, Inc. in October 2014. ZIVO Bioscience, Inc. is headquartered in Bloomfield Hills, Michigan.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas